New pill for rheumatoid arthritis enters first human tests
NCT ID NCT07266207
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested ARD-885, a new oral drug that targets two proteins involved in inflammation, in 94 healthy volunteers and people with rheumatoid arthritis. The main goal was to check safety and how the body processes the drug. Researchers gave single and multiple doses, and also looked at the effect of food. This is a first step to see if the drug is safe enough for larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARD-885 tablets (a drug that targets inflammation pathways)
What this could lead to
If successful, this could lead to a new oral treatment option for rheumatoid arthritis that helps control joint inflammation and pain.
What could go wrong
This is a very early Phase 1 trial focused on safety and dosing, not on effectiveness. The drug may not work or could have side effects. Results in healthy people may not apply to RA patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Affiliated Hospital of Anhui Medical University
Hefei, Guangdong, China